Shares of Alamar Biosciences (NASDAQ: ALMR) experienced a significant surge on Tuesday, climbing 31% following the release of its second-quarter financial results. The stock closed at $36.57, up 30.7% for the day, after reaching an intraday high of $38.54, a new 52-week peak. The rally was driven by the company's robust revenue growth and a favorable shift in its revenue mix toward higher-margin consumables.
Revenue Growth and Margin Expansion
Alamar reported second-quarter revenue of $29.4 million, an 82% increase compared to the same period last year. The standout performer was consumables, which brought in $15.5 million, a 147% year-over-year surge. Consumables now represent 52.6% of total revenue, up from 38.8% in the year-ago quarter. This shift toward consumables, which typically carry higher margins, helped boost the company's gross margin to 60%, up seven percentage points from 53% in the prior-year period.
The company's gross profit more than doubled to $17.7 million, reflecting the improved margin profile. However, operating expenses also rose sharply, increasing 89% to $31.3 million, outpacing revenue growth. As a result, Alamar reported an operating loss of $13.5 million, wider than the $7.9 million loss in the second quarter of 2025. The net loss also expanded to $13.2 million from $7.0 million.
Market Valuation and Guidance
Following the earnings release, Alamar's market capitalization closed at $2.53 billion, representing approximately 21.5 times the midpoint of its 2026 revenue guidance of $118 million. The company maintained its full-year revenue forecast of $116 million to $120 million, which implies a 59% increase over 2025. To hit the midpoint, Alamar will need to generate an average of $31.3 million in revenue per quarter in the second half, a modest 6.3% increase over the second quarter's performance.
The company's balance sheet remains solid, with $256.3 million in cash, short-term investments, and restricted cash, providing ample runway to support its commercial expansion. However, the widening operating losses indicate that the company's scale is not yet sufficient to cover its cost base.
Partnership Expansion and Analyst Reactions
In addition to the financial results, Alamar announced an expanded collaboration with the Alzheimer's Disease Data Initiative and Gates Ventures. The partnership will analyze 86,000 plasma samples, with the total dataset expected to surpass 140,000 samples by 2027. The initiative will utilize Alamar's NULISA platform and Neuro 220 panel, underscoring the scientific momentum behind the company's technology.
Following the report, several analysts updated their price targets. J.P. Morgan raised its target to $35, Stifel increased to $32, and Bank of America lifted its target to $31. TD Cowen and Leerink Partners also adjusted their targets to $34 and $35, respectively. Despite these revisions, all targets remain below Tuesday's closing price, reflecting the stock's sharp move.
Risks and Outlook
While the consumables growth is encouraging, Alamar continues to face significant risks. The company remains unprofitable, and its operating expenses are growing faster than revenue. A slowdown in instrument placements could eventually dampen demand for consumables, which are the key driver of recurring revenue. Moreover, the stock's high valuation, trading at over 21 times projected sales, leaves little room for error.
Investors will be watching closely to see if Alamar can sustain its consumables momentum and achieve its full-year guidance. The company's ability to manage operating expenses while scaling its commercial operations will be critical to its path to profitability.